irak

IRAK inhibitor 2 (IRAK-IN-2) is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK-4) for the study of inflammation-related diseases.

IRAK-4 protein kinase inhibitor 2 is a potent interleukin-1 receptor-associated kinase-4 (IRAK-4) inhibitor(IC50 = 4 μM).

IRAK inhibitor 4 is a compound that functions as an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). It specifically targets and inhibits the activity of IRAK4. The (trans) form of IRAK inhibitor 4 refers to its specific molecular configuration.

IRAK degrader-1 (example I-3) is a potent IRAK degrader [1] .

IRAK inhibitor 4 is an interleukin-1 receptor associated kinase 4 inhibitor.

IRAK-1-4 Inhibitor I is a dual inhibitor of IRAK4 and IRAK1.

IRAK inhibitor 6 is an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK-4, IC50: 160 nM).

IRAK inhibitor 3 is an interleukin-1 (IL-1) receptor-associated kinase (IRAK) modulator.

IRAK inhibitor 1 is an effective IRAK-4 inhibitor (IC50: 216 nM), is poorly active against JNK-1 (IC50: 3.801 μM) and JNK-2 (IC50>10 μM).

IRAK4-IN-20 is a potent and orally active IRAK4 inhibitor (IC50:3.55 nM). IRAK4-IN-20, which has anti-inflammatory, antitumor and anticancer effects, is often used to treat acute respiratory distress syndrome (ARDS).

IRAK4-IN-8 (VI-177) is an IRAK4 inhibitor for the study of diseases associated with cancer and inflammation.

IRAK4-IN-10 is a potent IRAK4 inhibitor (IC50: 1.5 nM) with potential anticancer and anti-inflammatory activities.IRAK4-IN-10 blocks MyD88 signaling and can be used for the study of autoimmune diseases and cancers.

PROTAC IRAK3 degrade-1 is a potent and selective degrader of IRAK3 ( IC 50 = 5 nM).

IRAK4-IN-4 (compound 15) inhibits cyclic GMP-AMP synthase (cGAS) with an IC50 of 2.1 nM.IRAK4-IN-4 is an interleukin-1 receptor–associated kinase 4 (IRAK4) inhibitor, has an IC50 of 2.8 nM.

PROTAC IRAK4 Ligand-3 serves as a ligand for PROTAC IRAK4 Degrader-7 and is utilized in cancer research [1].

PROTAC IRAK4 degrader-6 is a potent Cereblon-based compound designed to degrade interleukin-1 receptor-associated kinase 4 (IRAK4).

PROTAC IRAK4 degrader-4 (US20190192668A1, compound I-127) is a Cereblon-based PROTAC specifically designed to target and degrade interleukin-1 receptor-associated kinase 4 (IRAK4).

PROTAC IRAK4 degrader-3 is a PROTAC-induced IRAK4 degrader based on von Hippel-Lindau.

IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM.

PROTAC IRAK4 degrader-5 is a Cereblon-based IRAK4 degrader.

IRAK4-IN-24 (compound 16), a potent IRAK4 inhibitor, exhibits high clearance (Cl) and low oral bioavailability. It is utilized in research pertaining to inflammatory and autoimmune disorders.

IRAK4-IN-21 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 5 nM) and TAK1 (IC50: 56 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.17 μM. can be used to study autoimmune diseases, such as plaque psoriasis and psoriatic arthritis.

IRAK4-IN-12 (compound 37) is a potent inhibitor of IRAK4 (IC50: 0.015 μM) with cellular pIRAK4 potency (IC50: 0.5 μM).

IRAK4-IN-25 (compound 38), a potent oral IRAK4 inhibitor (IC50 = 7.3 nM) with low clearance (Cl = 12 mL/min/kg), effectively suppresses pro-inflammatory cytokine production and demonstrates favorable in vitro safety and ADME profiles. It is suitable for research on inflammatory and autoimmune disorders [1].

IRAK4-IN-22 is a selective, orally active, potent IRAK4 inhibitor that acts on IRAK4 (IC50: 3 nM) and TAK1 (IC50: 17 nM). IRAK4-IN-21 exhibits potent inhibition of IL-23 production with an IC50 value of 0.10 μM. IRAK4-IN-21 can be used to study autoimmune diseases, such as plaque psoriasis and psoriatic arthritis.

IRAK4-IN-11 (compound 6) is a potent inhibitor of IRAK4 with an IC 50 of 0.008 μM. IRAK4-IN-11 exhibits cell pIRAK4 potencies with an IC 50 of 0.19 μM [1].

PROTAC IRAK3 Degrade-1 (Compound 23) is a selective and potent IRAK3 degrader, demonstrating an IC50 value of 5 nM [1].

IRAK4-IN-26 (Compound 21), an IRAK4 inhibitor with an IC50 of 6.2 nM, exhibits an oral bioavailability of 21%. It is utilized for the study of inflammatory and autoimmune disorders [1].

IRAK4-IN-18 is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) (IC50: 15 nM). IRAK4-IN-18 inhibits LPS-induced IL23 production in THP and DC cells and blocks the development of arthritis in rats, a model of arthritis. IRAK4-IN-18 can be used to study arthritic diseases.

IRAK4-IN-14 is a selective, potent, orally active IRAK4 inhibitor (IC50: 0.003 μM) with favorable PK parameters in rats and mice. effect.

PROTAC IRAK4 Degrader-8 (Compound 2) is a PROTAC designed to target IRAK4 with an IC50 of 15.5 nM [1].

IRAK4-IN-19 is a potent inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) (IC50: 4.3 nM).IRAK4-IN-19 inhibits LPS-induced IL23 production in THP and DC cells and suppresses the development of arthritis in arthritis model rats.IRAK4-IN-19 can be used to study arthritic diseases.

IRAK4-IN-17 (Compound 5) is a highly potent inhibitor of IRAK4, exhibiting an impressive IC50 value of 1.3 nM [1]. This compound is particularly valuable for research focused on large B-cell lymphoma (DLBCL) [1].

IRAK4-IN-15 is a selective and potent IRAK4 inhibitor (IC50: 0.002 μM) with good human PK prediction and low intrinsic clearance.IRAK4-IN-15 in combination with Acalabrutinib exhibited potent synergistic in vitro activity against MyD88/CD79 double mutant ABC-DLBCL.

IRAK4-IN-9 (compound 73) is a highly potent inhibitor of IRAK4, displaying an impressive IC50 value of 1.5 nM. By blocking MyD88-dependent signaling, IRAK4-IN-9 exhibits promising potential for the investigation of inflammatory diseases, autoimmune diseases, and cancer [1].

IRAK4-IN-28 (compound 42), an orally-active IRAK4 inhibitor (IC50=8.9 nM), exhibits strong binding affinity with a Kd of 0.58 nM for the target enzyme. It is utilized for research purposes in the study of inflammation and autoimmune diseases [1].

IRAK4-IN-27 (Compound 22) is a potent and selective IRAK4 inhibitor, demonstrating an IC50 of 8.7 nM. It effectively suppresses cell growth and induces apoptosis in the MYD88 L265P diffuse large B-cell lymphoma (DLBCL) cell line, positioning it as a valuable agent for DLBCL research [1].

PROTAC IRAK4 Degrader-2 (Compound 9) is a PROTAC-based degrader that potently reduces IRAK4 levels, achieving a DC50 of 151 nM in peripheral blood mononuclear cells (PBMCs). It also notably decreases IRAK4 protein levels with a DC50 of 36 nM in the same cell type and inhibits several cytokines in PBMCs [1].

PROTAC IRAK4 degrader-7 (Compound I-417) is an orally administered agent with antitumor properties, functioning as a PROTAC IRAK4 degrader [1].

IRAK4-IN-13 (compound 21) is a selective and potent IRAK4 inhibitor (IC50: 0.6 nM). iRAK4-IN-13 has a high metabolic clearance, with an intrinsic human liver microsomal (HLM) clearance of 96 μL/min/mg.

PROTAC IRAK4 degrader-1 is a degrader of PROTAC interleukin-1 receptor-associated kinase 4 (IRAK4).

IRAK4-IN-7 (CA-4948) is a selective and potent IRAK4 kinase inhibitor with in vivo activity in a TLR4-induced cytokine release model.

IRAK4-IN-6 is a selective and orally efficacious inhibitor of IRAK4, demonstrating an IC50 value of 4 nM. This compound specifically targets MyD88 L265P mutant diffuse large B-cell lymphoma [1].

PROTAC IRAK4 ligand-1 is a synthetic ligand for interleukin-1 receptor-associated kinase 4.

IRAK4-IN-16 (compound 4) is a potent inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with an IC 50 of 2.5 nM. IRAK4-IN-16 exhibits cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC 50 values of 0.2, 0.2, 0.6, and 2.7 μM, respectively [1].

Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor that exhibits anti-inflammatory activity. edecessertib can be used to study rheumatoid arthritis (RA) and lupus erythematosus (LE).

AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL).

JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK-1.

Zimlovisertib (PF-06650833) is an effective, selective and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) (IC50s: 0.2 and 2.4 nM in the cell and PBMC assay).

HS-243 is an inhibitor of IRAK-4 and IRAK-1 with IC50s of 20 and 24 nM. HS-243 shows anti-inflammatory and anticancer activity.